UIC leads multi-center collaborative to help communities affected by COVID-19

The University of Illinois Chicago has been selected by the National Institutes of Health as the principal site of a multi-center collaborative in the Chicago area that will bolster research and outreach to help communities disproportionately affected by COVID-19.

As part of the NIH's Community Engagement Alliance, or CEAL, Against COVID-19 Disparities initiative, the UIC-led team will focus on strengthening COVID-19 vaccine confidence and access in Chicago-area Black and Latino communities, as well as improving access to testing, treatment and opportunities for clinical trial participation.

In Chicago, rates of COVID-19 cases are greatest among Black and Latino residents, significantly outpacing rates among white residents. Despite this and efforts in the city to deliver the vaccine to vulnerable communities, early data on vaccinations show lower rates of COVID-19 vaccination among Black and Latino adults.

Black and Latinx communities have historically had unequal access to health care services and research. We will focus on these issues of structural racism, with the goal of improving vaccination rates and, importantly, we will do this in partnership with the people and organizations that are already in the communities working as leaders and trusted messengers."

Dr Molly Martin, Principal Investigator and Associate Professor of Pediatrics, College of Medicine, University of Illinois at Chicago

The team, called the Chicagoland COVID Collaborative, includes co-principal investigators from Loyola University, Equal Hope, Northwestern University, Rush University Medical Center, Sinai Urban Health Center and the University of Chicago. The collaborative is supported by a $1.4 million NIH grant.

In addition to its goals of increasing vaccine uptake and engagement with health care providers for testing, treatment and trials, the collaborative also will leverage best practices in community-engaged research and implementation science to support and test various adaptive interventions to address structural barriers to health care services in Chicago and surrounding areas.

"Community engagement is about being present, listening and meeting the needs of communities in a lasting way -- it's about strengthening opportunities and programs in partnership with communities, validating what they have and know, and ensuring that services and programs are meaningful and sustainable," Martin said.

For example, Martin said the team will work with community partners to create an inventory of vaccine awareness, education, and distribution programs and evaluate these programs to help identify which strategies are more effective.

"If a lot of effort is going into a program but the impact is low, we want to work with our partners and the data to understand why. We will support them to describe barriers and potential solutions. We will help identify critical resources linked to success and pathways for obtaining and maintaining those resources. Answering these kinds of questions moves us closer to more equitable health access and outcomes, for COVID-19 and beyond," Martin said.

Martin says that while increasing vaccine uptake is a focus now, the collaborative is designed to address all kinds of barriers and public health goals.

"The COVID-19 pandemic has made clear the inequities cemented into the foundations of our social system; the consequences of these inequities in access, trust and engagement with the health care system affect us all," Martin said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients